How Long Does — Rituximab Take to Work?

Your doctor is likely tracking the biological response before structural change becomes visible. Rituximab clears B-cells from the blood and lymph nodes within the first few weeks — measurable in blood counts even before a scan shows tumour shrinkage. Formal response assessment happens after several cycles, not after the first dose. An encouraging word from your team at an early visit is usually based on your symptoms, blood results, and overall clinical picture, not on imaging.

Not necessarily, and it is not something you can judge from symptoms alone. Response speed varies between people and between cancer types. The reliable way to assess response is the mid-treatment and end-of-treatment scans, read alongside your blood results and clinical picture. If you are worried that nothing seems to be changing, raise it at your next appointment. Your oncologist can tell you what the data shows, rather than leaving you to interpret your own symptoms.

The mid-treatment scan — usually a PET-CT — compares your current images against the baseline taken before treatment started. It shows whether the areas of disease have reduced in size or metabolic activity. The result helps your oncologist decide whether to continue with the same plan, adjust it, or in some cases intensify. For most B-cell lymphomas, NCCN and ESMO guidance sets out what different levels of mid-treatment response mean for the rest of the plan.

Yes. The drug continues to deplete B-cells for a period after the last dose. For some cancer types — including follicular lymphoma — maintenance rituximab may be recommended, where the drug is given at lower frequency after the initial course ends. ESMO guidance supports maintenance in certain settings to extend the benefit of first-line treatment. Whether maintenance applies to you depends on your cancer type, your response, and your overall situation. Ask your oncologist whether it is relevant to your plan.

You would not typically know from symptoms alone, at least not early on. Progression is usually picked up on routine scans and blood tests rather than sudden changes. Signs that might prompt a scan sooner include returning B symptoms — fevers coming back, new night sweats, unexplained weight loss — or lymph nodes that feel bigger again. If anything like this happens between scheduled appointments, contact your team rather than waiting. Progression does not mean there are no more options; your oncologist will explain what comes next.

Rituximab has a long half-life and remains in circulation for several weeks after the last infusion. Its effect on B-cells persists for longer still — B-cell recovery typically takes several months to complete after treatment ends. During this time your immune system remains affected, which is why your team continues to monitor your blood counts and advise on infection precautions even after your final dose. Follow their guidance on vaccinations and contact with people who are unwell.